Skip to content
Film Television Auditions – Lifestyle
Author:
BridgeBio Pharma, Inc.
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
May 11, 2026
←
Previous Page
1
2
3
4